Most Clicked StoriesMore >


Filing of first biosimilar offers glimpse of possible savings for U.S.

PCMA SmartBrief | Jul 25, 2014

The FDA application filed Thursday by Sandoz for a biosimilar drug is just the beginning in realizing the huge savings that biosimilars can bring to the U.S. compared with expensive biologics, Jason Millman writes. The U.S. biosimilars market's development will be key amid payers' concerns about a projected increase in the country's drug spending over the next few years, Millman writes. Washington Post (tiered subscription model), The (07/24)


Regulatory progress for Sandoz's filgrastim bodes well for future biosimilar filings

PCMA SmartBrief | Jul 28, 2014

High-cost hep C drugs will drive up Medicare Part D premiums, spending

PCMA SmartBrief | Jul 30, 2014

Study: Hepatitis C drugs could boost annual drug spending by $5.8B

PCMA SmartBrief | Jul 31, 2014

Feds settle on penalty caps for not buying health coverage

PCMA SmartBrief | Jul 28, 2014

Court rulings prompt states to demonstrate ownership of exchanges

PCMA SmartBrief | Jul 28, 2014

Activists criticize Gilead's pricing of hepatitis C drug Sovaldi

PCMA SmartBrief | Jul 28, 2014

Calif. considers rules for translating Rx labels

PCMA SmartBrief | Jul 30, 2014

New Milliman study: Hepatitis C drugs could increase Medicare Part D spending by $2.9 billion to $5.8 billion in 2015

PCMA SmartBrief | Jul 30, 2014

Medicare trust fund on pace to last until 2030, government says

PCMA SmartBrief | Jul 29, 2014


Find PCMA SmartBrief Issues by Date:





Sign up for PCMA SmartBrief



Designed specifically for PBM industry professionals, PCMA SmartBrief is a FREE, daily e-mail newsletter. It provides the the most relevant and actionable PBM industry news in a quick, easy to read format. Learn more